MRA three-year confidence building period will be "entirely open process" -- FDA's Gray.
This article was originally published in The Tan Sheet
Executive Summary
MRA CONFIDENCE BUILDING PERIOD WILL BE "ENTIRELY OPEN," FDA says, as it pertains to the agency's determinations of regulatory equivalence during the implementation of the U.S./European Union mutual recognition agreement, Office of Compliance Director Stephanie Gray told the Drug Information Association annual meeting in Boston June 8-11. FDA plans "to provide for additional opportunities to follow and comment on the implementation of the MRA," Gray said. "We think it is very important to have an entirely open process so that people understand why decisions were made."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning